Abstract | BACKGROUND AND OBJECTIVES: METHODS: RESULTS: A pharmacokinetic analysis of imiglucerase showed a two-compartment model with a high peak followed by a two-phase exponential decay (fast phase half-life: 0.36 days; slow phase half-life: 9.7 days) leading to a median 1.4-fold increase in glucocerebrosidase intra-monocyte activity from the pre-treatment activity (p = 0.04). In patients receiving long-term treatment, for whom the imiglucerase dose per infusion was chosen on the basis of disease aggressiveness/response, imiglucerase clearance correlated with the administered dose. However, the residual glucocerebrosidase intra-monocyte activity value was dose independent, suggesting that the maintenance of imiglucerase residual activity is patient specific. Endogenous pre-treatment glucocerebrosidase intra-monocyte activity was the most informative single parameter for distinguishing patients without (n = 10) and with a clinical indication (n = 17) for starting enzyme replacement therapy (area under the receiver operating characteristic curve: 0.912; 95% confidence interval 0.8-1; p < 0.001), as confirmed also by a factorial analysis of mixed data. CONCLUSION:
|
Authors | Juliette Berger, Marie Vigan, Bruno Pereira, Thu Thuy Nguyen, Roseline Froissart, Nadia Belmatoug, Florence Dalbiès, Agathe Masseau, Christian Rose, Christine Serratrice, Yves-Marie Pers, Ivan Bertchansky, Fabrice Camou, Monia Bengherbia, Céline Bourgne, Catherine Caillaud, Magali Pettazzoni, Amina Berrahal, Jérôme Stirnemann, France Mentré, Marc G Berger |
Journal | Clinical pharmacokinetics
(Clin Pharmacokinet)
Vol. 58
Issue 4
Pg. 469-482
(04 2019)
ISSN: 1179-1926 [Electronic] Switzerland |
PMID | 30128966
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glucosylceramidase
- imiglucerase
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Child
- Enzyme Replacement Therapy
- Female
- Gaucher Disease
(drug therapy, metabolism)
- Glucosylceramidase
(metabolism, pharmacokinetics, therapeutic use)
- Humans
- Male
- Middle Aged
- Models, Biological
- Monocytes
(metabolism)
- Precision Medicine
- Young Adult
|